Swissmed · Market Intelligence

Market overview

Loading…

Sell-out value (ACT)

—

Sell-out units (ACT)

—

Target attainment

—

Stock turnover (Sonar)

—

What drove sell-out — brand contribution

$ actual, by period selector

Sell-in vs sell-out

SISO

Sell-in / Sell-out

Tier A sell-out planning facts (net USD) · Sell-in invoicing 2020–2026 (gross AZN, national) — units are the only cross-comparable measure

Sell-out ACT vs TGT

ActualTarget

Brand performance

value, USD net

Brand	ACT units	ACT $	TGT $	vs TGT	Region

Sell-in by brand

Brand	Section	SI units	SI value (gross AZN)	vs PY units

Geography

13 real Swissmed territories · Tier A planning facts by region

Sell-out by region

ACT $ · share of national total

Regional detail

ACT vs TGT $ by region, selected period

Region	ACT $	TGT $	vs TGT

Baku sub-districts

Avromed feed only · May 2026 · AZN value

Analytics

Seasonality, price/volume decomposition & target quality — precomputed from Tier A planning facts

Seasonality heatmap — sell-out ACT $

All years 2021–2026

Brand

Cell shade scales with monthly ACT $ within the selected view. National view sums all brands; brand views cover the top 8 brands by 2021–2025 ACT $.

Price–volume decomposition

Volume effectPrice effect

Years

(1 + USD growth) = (1 + volume effect) × (1 + price effect) — exact decomposition. Implied price = ACT $ ÷ ACT units, from Tier A national planning facts. Right-hand label = total USD growth.

Target quality — 2025 attainment vs target size

Dots persistently above the 150% line suggest sandbagged targets; below 60% suggest unrealistic targets. One dot per region × brand.

Category rollup

ABC / XVA matrix

revenue tier × demand volatility2021–2025 aggregate

Brand	Revenue class	Volatility	Total $ 2021–2025	CV

A/B/C = revenue tier (Pareto), X/V/A_volatile = demand volatility (CV of monthly units). Brands with insufficient monthly history render as "insufficient data" (muted).

Forecast accuracy — MAPE & bias

Brand	MAPE %	Bias %	Direction	Months used

Bias % positive = ACT consistently exceeds target; negative = ACT consistently misses target. Sorted worst-MAPE-first.

Growth concentration — where did 2025 growth come from

national growth $, sorted desc

Brand	National growth $	Top region	Top-region share	Concentration

Concentrated = >50% of a brand's national growth came from one region. Hover a row for the top-3 region breakdown. ⚠ = one or more regions declined while the brand grew nationally.

Market share — Azerbaijan (SMaRT panel)

SMaRT · May-2026 snapshot — not by Year

Competitor landscape — top rivals by molecule

SMaRT · May-2026 snapshot — not by Year

Molecule

Corporation	Brand	Units (2026 YTD)	Value $ (2026 YTD)	Growth vs PY

Excludes Swissmed's own (Sandoz) rows — shows who else sells the same molecule in Azerbaijan. Top 10 by 2026 YTD value.

Brands & SKUs

Pick a brand to drill into its dosages/SKUs, from real planning_facts

Buy-ins & stock

Sonar distributor stock feed (UMUMI sheet) — sold units, remaining stock, turnover

Stock turnover by product

sold vs remaining, unitsMay-2026 stock snapshot — not by Year

Sonar stock detail

real May-2026 stock snapshot · units only

Product	Sold	Remaining	Turnover

Months of cover

remaining stock ÷ avg monthly sell-out · sorted tightest firstMay-2026 stock snapshot — not by Year

Product	Remaining	Avg mo. sell-out	Cover (mo)	Status

Distributor detail

Sell-Out actuals (Tier B, distributor/pharmacy-reported) from 6 chains · May 2026 · no targets, units-only unless noted

By chain × brand × region

select a chain in the top bar to filterTier B · May 2026 only — not by Year

Chain	Brand	Region	Qty	Value	Customers

Distribution reach

Tier B · May 2026 only — not by Year

Brand	Customers	Qty	Reach

Customer concentration

Tier B · May 2026 only — not by Year

Chain

Daily pulse — May 2026

Avromed qtyLek/Azerimed qty

Supervisor leaderboard

Avromed field force · May 2026 · top 15 by AZN value

Supervisor	Value	Qty	Customers	Brands

Data sources

The real 8-file inventory this dashboard is built from

Source files

Known gap — competitor / market share

pending

Competitor / market-share data: not present in any current source file — all 8 files track Swissmed-supplied products only. A market share module requires an external panel feed (e.g. IQVIA) — pending from Swissmed.